リソース
ブログ
Hongeneとともに、RNAの最前線へ — 最先端の科学、技術革新、業界動向をお届けします。
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this is Zilebesiran, a novel RNA interference (RNAi) therapeutic that is currently advancing through late-stage clinical trials for the treatment of hypertension [1]. This illustrates a […]
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
Jul 8, 2026David Butler, CTO
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this is Zilebesiran, a novel RNA interference (RNAi) therapeutic that is currently advancing through late-stage clinical trials for the treatment of hypertension [1]. This illustrates a […]
Mar 18, 2025David Butler, CTO
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
- 10 / ページ
- 20 / ページ
- 50 / ページ